loading
Tandem Diabetes Care Inc stock is currently priced at $36.90, with a 24-hour trading volume of 113.97K. It has seen a +4.63% increased in the last 24 hours and a +4.12% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $35.28 pivot point. If it approaches the $36.83 resistance level, significant changes may occur.
Previous Close:
$35.24
Open:
$37.25
24h Volume:
113.97K
Market Cap:
$2.28B
Revenue:
$747.72M
Net Income/Loss:
$-222.61M
P/E Ratio:
-11.42
EPS:
-3.23
Net Cash Flow:
$-83.41M
1W Performance:
+16.20%
1M Performance:
+4.12%
6M Performance:
+104.95%
1Y Performance:
-6.85%
1D Range:
Value
$36.84
$38.00
52W Range:
Value
$13.82
$40.74

Tandem Diabetes Care Inc Stock (TNDM) Company Profile

Name
Name
Tandem Diabetes Care Inc
Name
Phone
858-366-6900
Name
Address
11045 Roselle Street, San Diego, CA
Name
Employee
574
Name
Twitter
@tandemdiabetes
Name
Next Earnings Date
2024-05-22
Name
Latest SEC Filings
Name
TNDM's Discussions on Twitter

Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-04-23 Downgrade Citigroup Buy → Neutral
May-05-23 Downgrade BofA Securities Neutral → Underperform
Apr-24-23 Downgrade Raymond James Outperform → Mkt Perform
Mar-29-23 Initiated UBS Neutral
Jan-26-23 Initiated Wolfe Research Peer Perform
Nov-15-22 Upgrade Wells Fargo Underweight → Equal Weight
Oct-18-22 Initiated Barclays Overweight
Oct-12-22 Initiated Jefferies Buy
Aug-09-22 Downgrade Wells Fargo Overweight → Underweight
Mar-02-22 Resumed BofA Securities Neutral
Jan-19-22 Upgrade Wells Fargo Equal Weight → Overweight
Jul-21-21 Resumed Cowen Outperform
May-25-21 Initiated Barclays Underweight
Dec-15-20 Downgrade Wells Fargo Overweight → Equal Weight
Aug-20-20 Initiated Wells Fargo Overweight
Jul-31-20 Upgrade Guggenheim Neutral → Buy
Jul-06-20 Upgrade Citigroup Neutral → Buy
Jun-18-20 Reiterated Raymond James Outperform
Apr-24-20 Downgrade SVB Leerink Outperform → Mkt Perform
Mar-23-20 Downgrade Guggenheim Buy → Neutral
Mar-05-20 Initiated Citigroup Neutral
Feb-06-20 Initiated Raymond James Outperform
Feb-04-20 Downgrade Robert W. Baird Outperform → Neutral
Oct-18-19 Initiated Guggenheim Buy
Oct-04-19 Upgrade UBS Neutral → Buy
May-17-19 Reiterated BofA/Merrill Neutral
May-13-19 Initiated SVB Leerink Outperform
Mar-08-19 Initiated BMO Capital Markets Outperform
Mar-05-19 Reiterated BofA/Merrill Neutral
Feb-27-19 Reiterated Lake Street Buy
Nov-21-18 Upgrade Robert W. Baird Neutral → Outperform
Sep-26-18 Reiterated Dougherty & Company Buy
Sep-26-18 Reiterated Piper Jaffray Overweight
View All

Tandem Diabetes Care Inc Stock (TNDM) Financials Data

Tandem Diabetes Care Inc (TNDM) Revenue 2024

TNDM reported a revenue (TTM) of $747.72 million for the quarter ending December 31, 2023, a -6.68% decline year-over-year.
loading

Tandem Diabetes Care Inc (TNDM) Net Income 2024

TNDM net income (TTM) was -$222.61 million for the quarter ending December 31, 2023, a -135.33% decrease year-over-year.
loading

Tandem Diabetes Care Inc (TNDM) Cash Flow 2024

TNDM recorded a free cash flow (TTM) of -$83.41 million for the quarter ending December 31, 2023, a -1,210% decrease year-over-year.
loading

Tandem Diabetes Care Inc (TNDM) Earnings per Share 2024

TNDM earnings per share (TTM) was -$3.44 for the quarter ending December 31, 2023, a -132.43% decline year-over-year.
loading
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:flex insulin delivery system that includes t:flex pump, its 480-unit disposable insulin cartridge, and an infusion set; t:slim X2 with G5 integration; and Tandem Device Updater, a PC and Mac-compatible tool that allows users to update their pump's software. In addition, the company offers t:connect diabetes management application, a cloud-based data management application, which provides a visual way to display therapy management data from the pump and supported blood glucose meters for users, their caregivers, and their healthcare providers; t:lock cartridge and infusion set products; and various pump accessories. Its products in development include automated insulin delivery systems; t:slim X2 with Basal IQ; t:slim X2 with control IQ; t:sport insulin delivery system; and connected (mobile) health mobile application. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was founded in 2006 and is headquartered in San Diego, California.
medical_devices PHG
$28.46
price up icon 35.33%
medical_devices STE
$205.75
price up icon 0.84%
$307.03
price down icon 0.26%
medical_devices ZBH
$120.48
price up icon 0.85%
$127.90
price up icon 3.03%
medical_devices EW
$85.48
price down icon 1.05%
Cap:     |  Volume (24h):